Erratum to: Invest New Drugs (2014) 32:535–541
DOI 10.1007/s10637-014-0065-x
In the original version of this article, we have had unintentional mistakes for measuring progression-free survival (PFS). The corrected progression-free survival was 3.7 months (95% CI 2.1-5.3). So, we revised Table 3, Figure 2a, c and manuscript (Results section and Discussion section). We also added secondary endpoints which had been described in the study protocol according to the recommendation by the sponsor (Merck).
a Progression-free survival b Overall survival c Overall survival according to codon 12 and codon 13 KRAS mutations
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at http://dx.doi.org/10.1007/s10637-014-0065-x.
Rights and permissions
About this article
Cite this article
Lee, J., Hong, Y.S., Hong, J.Y. et al. Erratum to: Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. Invest New Drugs 33, 269–270 (2015). https://doi.org/10.1007/s10637-014-0162-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-014-0162-x